trending Market Intelligence /marketintelligence/en/news-insights/trending/3hdYAmvgUY_vSHWJRDfxAQ2 content esgSubNav
In This List

CK Hutchison plans to cut stake in Chi-Med below 50% via stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CK Hutchison plans to cut stake in Chi-Med below 50% via stock offering

Industrial conglomerate CK Hutchison Holdings Ltd. is planning to reduce its stake in Hutchison China MediTech Ltd. to below 50% by selling about 1.3% of the total outstanding shares of the biopharmaceutical company in a public offering.

Hong Kong-based CK Hutchison plans to reduce its stake to 49.9% from 51.1% and maintain its shareholding in the cancer therapy developer Chi-Med as a strategic investment. CK Hutchison priced the shares, which are being sold through an underwritten public offering, at $17.65 per American depositary share, which represent five ordinary shares with a value of 10 cents.

In April, CK Hutchison said it intends to cut its stake to below 50% to improve liquidity in Chi-Med's shares and that the business would no longer be a consolidated unit in its financial statements.

CK Hutchison said in a Sept. 30 press release that upon completion of the underwritten offering, it has no intention of selling additional Chi-Med shares for the foreseeable future.